Lv5
1546 积分 2024-04-01 加入
A Real-World Study: Effect of the Third-Line Therapy of Fruquintinib or Regorafenib Therapy Versus Rechallenge Chemotherapy in Metastatic Colorectal Cancer
1天前
求助中
HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8+ T cell glutamine metabolism via KIR3DL3 interaction
12天前
已完结
HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8+ T cell glutamine metabolism via KIR3DL3 interaction
1个月前
已完结
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)
1个月前
已完结
Negative selection — clearing out the bad apples from the T-cell repertoire
2个月前
已完结
Moving towards personalized treatments of immune-related adverse events
2个月前
已完结
Capturing “source” and “evolution”: A 5-year recurrence risk prediction model for nasopharyngeal carcinoma based on integrated radiomic spatial heterogeneity of primary tumor and lymph nodes
2个月前
已关闭
Impact of consolidation immunotherapy after definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a real-world multicenter study
5个月前
已完结
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
5个月前
已完结
Iparomlimab and Tuvonralimab: First Approval
5个月前
已完结
皖公网安备34019202002308
